These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 27185091)
1. Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature. Daste A; Gross-Goupil M; Quivy A; François L; Bernhard JC; Ravaud A Clin Genitourin Cancer; 2016 Oct; 14(5):e525-e527. PubMed ID: 27185091 [No Abstract] [Full Text] [Related]
2. Targeted Therapy for Metastatic Renal Cell Carcinoma. Afriansyah A; Hamid AR; Mochtar CA; Umbas R Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997 [TBL] [Abstract][Full Text] [Related]
3. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Rini BI Curr Oncol Rep; 2006 Mar; 8(2):85-9. PubMed ID: 16507216 [TBL] [Abstract][Full Text] [Related]
4. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893 [TBL] [Abstract][Full Text] [Related]
8. Axitinib (Inlyta) for advanced renal cell carcinoma. Med Lett Drugs Ther; 2012 Jun; 54(1392):47-8. PubMed ID: 22683928 [No Abstract] [Full Text] [Related]
9. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616 [TBL] [Abstract][Full Text] [Related]
10. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? Goldstein R; Pickering L; Larkin J Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625 [TBL] [Abstract][Full Text] [Related]
11. SU11248 and AG013736: current data and future trials in renal cell carcinoma. Rini BI Clin Genitourin Cancer; 2005 Dec; 4(3):175-80. PubMed ID: 16425985 [TBL] [Abstract][Full Text] [Related]
12. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment. Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560 [TBL] [Abstract][Full Text] [Related]
13. Signaling inhibitors in metastatic renal cell carcinoma. Escudier B Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338 [TBL] [Abstract][Full Text] [Related]
15. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264 [TBL] [Abstract][Full Text] [Related]
16. Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. George DJ Clin Cancer Res; 2007 Jan; 13(2 Pt 2):753s-757s. PubMed ID: 17255305 [TBL] [Abstract][Full Text] [Related]
17. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389 [TBL] [Abstract][Full Text] [Related]
18. Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal. Teo M; Downey FP; McDermott RS Clin Genitourin Cancer; 2013 Jun; 11(2):198-200. PubMed ID: 23276590 [No Abstract] [Full Text] [Related]
19. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510 [TBL] [Abstract][Full Text] [Related]